EP3355971A1 - Electrolyte adjustment infusion system and method - Google Patents
Electrolyte adjustment infusion system and methodInfo
- Publication number
- EP3355971A1 EP3355971A1 EP16788434.5A EP16788434A EP3355971A1 EP 3355971 A1 EP3355971 A1 EP 3355971A1 EP 16788434 A EP16788434 A EP 16788434A EP 3355971 A1 EP3355971 A1 EP 3355971A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- control unit
- infusion fluid
- signals
- patient
- fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003792 electrolyte Substances 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 15
- 238000001802 infusion Methods 0.000 title claims description 16
- 239000003978 infusion fluid Substances 0.000 claims abstract description 81
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 18
- 230000001276 controlling effect Effects 0.000 claims abstract description 15
- 230000033228 biological regulation Effects 0.000 claims abstract description 7
- 230000001105 regulatory effect Effects 0.000 claims abstract description 5
- 239000012530 fluid Substances 0.000 claims description 43
- 239000003814 drug Substances 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 20
- 239000011734 sodium Substances 0.000 claims description 16
- 229910052708 sodium Inorganic materials 0.000 claims description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 12
- 229910052700 potassium Inorganic materials 0.000 claims description 12
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 11
- 230000036760 body temperature Effects 0.000 claims description 11
- 239000011591 potassium Substances 0.000 claims description 11
- 230000036772 blood pressure Effects 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 2
- 230000033764 rhythmic process Effects 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000012503 blood component Substances 0.000 claims 1
- 239000000306 component Substances 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000002631 hypothermal effect Effects 0.000 description 9
- 206010021113 Hypothermia Diseases 0.000 description 7
- 206010008531 Chills Diseases 0.000 description 6
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 208000030886 Traumatic Brain injury Diseases 0.000 description 5
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 5
- 102000002852 Vasopressins Human genes 0.000 description 5
- 108010004977 Vasopressins Proteins 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000000084 colloidal system Substances 0.000 description 5
- 238000007726 management method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000003204 osmotic effect Effects 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229960003726 vasopressin Drugs 0.000 description 5
- 208000010496 Heart Arrest Diseases 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003722 extracellular fluid Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 230000009529 traumatic brain injury Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000476 body water Anatomy 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000537 electroencephalography Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000002977 intracellular fluid Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XFDJYSQDBULQSI-QFIPXVFZSA-N (R)-doxapram Chemical compound C([C@H]1CN(C(C1(C=1C=CC=CC=1)C=1C=CC=CC=1)=O)CC)CN1CCOCC1 XFDJYSQDBULQSI-QFIPXVFZSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 208000003450 Neurogenic Diabetes Insipidus Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000037037 animal physiology Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 210000000120 body fluid compartment Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000028235 central diabetes insipidus Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000010889 donnan-equilibrium Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960002955 doxapram Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 208000018548 hypothalamic dysfunction Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 201000005119 neurohypophyseal diabetes insipidus Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 208000007645 potassium deficiency Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- -1 protein and glycogen Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/44—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for cooling or heating the devices or media
- A61M5/445—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for cooling or heating the devices or media the media being heated in the reservoir, e.g. warming bloodbags
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
- A61M2005/1726—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure the body parameters being measured at, or proximate to, the infusion site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3334—Measuring or controlling the flow rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3368—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/005—Parameter used as control input for the apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/1407—Infusion of two or more substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/1414—Hanging-up devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/16831—Monitoring, detecting, signalling or eliminating infusion flow anomalies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/16877—Adjusting flow; Devices for setting a flow rate
Definitions
- the invention is directed to a device and methods for controlling and managing administration of infusion fluid, in particular for temperature regulation therapy, such as hypothermia treatment.
- hypothermia A condition in which the body's core temperature drops below that required for normal metabolism and body functions is usually called hypothermia. This is generally considered to be less than 35.0°C (95.0°F). Characteristic symptoms depend on the temperature.
- TTM Targeted temperature management
- therapeutic hypothermia or protective hypothermia is an active treatment that tries to achieve and maintain a specific body temperature in a person for a specific duration of time in an effort to improve health outcomes. This is done in an attempt to reduce the risk of tissue injury from the lack of blood flow. Periods of poor blood flow may be due to cardiac arrest or the blockage of an artery by a clot, such as those that may occur during a stroke.
- Targeted temperature management improves survival and brain function following resuscitation from cardiac arrest.
- Targeted temperature management following traumatic brain injury has shown mixed results, with some studies showing benefits in survival and brain function, while others show no clear benefit. While associated with some complications, these are generally mild. Targeted temperature management can advantageously prevent brain injury by several methods including decreasing the brain's oxygen demand, reducing the proportion of neurotransmitters like glutamate, as well as reducing free radicals that might damage the brain.
- the lowering of body temperature may be accomplished by many means, including the use of cooling blankets, cooling helmets, cooling catheters, ice packs and ice water lavage.
- the disclosure generally relates to a device and method for controlling a temperature of a patient by an infusion of fluid.
- Said device comprises a supply of infusion fluid, a body temperature input adapted to receive the actual body temperature of the patient and an additional input adapted to receive at least one additional parameter representing the actual physiological state of the patient.
- the device comprises a control unit communicating with said body temperature input, and said additional input and at least one actuator which is in fluid communication with said supply and which controls the actual flow rate and/or actual temperature of the infusion fluid in accordance with at least one control signal of said control unit.
- Document US7896834 B2 discloses a pump system selectably controlling the temperature, flow rate, flow volume, and flow pressure of a fluid being infused into a patient's body.
- the apparatus comprises means for delivering a predetermined volume or halting device operation when an excessive volume has been infused.
- Document US8672884 B2 discloses methods for introducing fluids into a body cavity for hypothermic treatment.
- at least one of the rate or volume of infusate is configured to increase a mean patient blood pressure.
- the infusion parameter is at least one of a flow rate, a pressure, a total infused volume, an inflow duty cycle or a hypothermic solution temperature.
- Infusing a solution into the blood stream of a patient will inherently affect the electrolytic balance of the blood, if the electrolytic profile of the infusion solution is not identical to that of the blood of the patient.
- the human body has functions to adjust for fluctuations in the concentration of cellular and extracellular electrolytes that result from dietary intake, metabolic activity and environmental stress, in order to keep these within narrow limits. It is especially critical that proper osmotic balance is maintained between intracellular and extracellular environment.
- Temperature regulation therapy such as therapeutic hypothermia treatment by infusion, frequently requires continuous infusion for one or more days and even for several days. It is an important therapeutic requirement that electrolytic balance is not jeopardized and that undue stress due to lowering of electrolyte concentration is minimized.
- the present invention provides an improved device for controlling and managing administration of infusion fluid that takes account of the electrolytic balance requirements of the human body.
- the device of the invention regulates and monitors overall electrolytic component administered to a patient and provides recommendations for type of infusion fluid during continued temperature therapy and/or directly controls the type of infusion fluid being administered in order to optimize the electrolyte content of administered infusion fluid.
- electrolyte refers to a substance whose components dissociate in solution into positively and negatively charged ions (cation and anion), and thus the term electrolytic component refers to any such component of an electrolyte.
- Infusion fluid refers to any fluid administered intravenously to a patient.
- Substances that may be infused intravenously include volume expanders, blood-based products, blood substitutes, medications and nutrition.
- Infusion solutions can be broadly divided in crystalloid and colloid solutions. Crystalloids are aqueous solutions of mineral salts or other water-soluble small molecules that readily diffuse across semi-permeable membranes. Colloids contain larger colloid molecules, such as, but not limited to albumin, other blood proteins, gelatin, etc.
- infusion solutions as defined herein include but are not limited to both crystalline solutions such as saline solutions or other type of conventional IV solutions (such as but not limited to those examples shown in Table 1), dissolved drugs or the like, and any type of colloid solution as well, administered to a patient via intravenous infusion.
- the average daily fluid intake is about 2.5 L.
- the amount needed to replace losses from the urine and other sources is about 1 to 1.5 L/day in healthy adults.
- Other natural water losses are mostly regular losses from the skin and lungs ("insensible loss"), about 0.4 to 0.5 mL/kg/h on average or about 650 to 850 mL/day in a 70-kg adult.
- insensible loss When a person has fever, another 50 to 75 mL/day may be lost for each degree C above normal temperature.
- GI losses are generally negligible, except when marked vomiting, diarrhea, or both occur. Sweat losses can be significant during environmental heat exposure or excessive exercise.
- Water intake is regulated by thirst. Thirst is triggered by receptors in the anterolateral hypothalamus that respond to increased plasma osmolality (as little as 2%), or decreased body fluid volume. Rare hypothalamic dysfunction decreases capacity for thirst.
- Vasopressin Water excretion by the kidneys is regulated primarily by vasopressin (ADH). Vasopressin is released by the posterior pituitary and results in increased water reabsorption in the distal nephron. Vasopressin release is stimulated by increased plasma osmolality, decreased blood volume, decreased blood pressure, and stress. Vasopressin release may be impaired by certain substances (eg, ethanol, phenytoin) and by central diabetes insipidus. Water intake decreases plasma osmolality. Low plasma osmolality inhibits vasopressin secretion, allowing the kidneys to produce dilute urine. Water and sodium balance are closely interdependent. Total body water is about 60% of body weight in average weight in men and about 50% in women.
- ADH vasopressin
- intracellular fluid intracellular fluid
- extracellular fluid extracellular fluid
- ICF intracellular fluid
- ECF extracellular fluid
- the major intracellular cation is potassium (K).
- the major extracellular cation is sodium (Na).
- Average concentrations of intracellular and extracellular cations are the following : K intracellular: 140 mEq/L, K extracellular 3.5 to 5 mEq/L, Na intracellular 12 mEq/L, Na extracellular 140 mEq/L.
- Osmolarity is the term defining concentration of combined solutes in water, as amount of solute per L. In bodily fluids, this is similar to osmolality, which is the amount of solute per kg of solution. Water crosses cell membranes freely from areas of low solute concentration to areas of high solute concentration. Thus, osmolality tends to equalize across different body fluid compartments, resulting primarily from movement of water, not solutes. Solutes such as urea that freely diffuse across cell membranes have little or no effect on water shifts (little or no osmotic activity), whereas solutes that are restricted primarily to one fluid compartment, such as Na and K, have the greatest osmotic activity. Tonicity, or effective osmolality, reflects osmotic activity and determines the force drawing water across fluid compartments defined as the osmotic force.
- the invention provides in one aspect a device for controlling and managing administration of infusion fluid(s) for temperature regulation therapy, wherein the device comprises at least one flow control unit for regulating flow rate of infusion fluid(s), and at least one control unit for receiving input signals and providing output signals.
- the control unit is configured to receive input signals that define infusion fluid to be administered or which is being administered, and to store such information, and provide output signals based on said received input signals.
- the output signals can in some embodiments affect the delivery of infusion fluid in order to deliver fluid with certain desired electrolyte content and/or alter the flow of fluid to alter the electrolyte content.
- the output signals comprise signals indicating recommendations for the therapy, at least including type of infusion fluid.
- the control unit can, in certain embodiments, provide signals to the flow control unit, to halt delivery or otherwise adjust delivery, e.g. change from one type of fluid to another, as further described herein.
- the flow control unit refers to a device or arrangement that enables the device to actively maintain a certain flow rate, i.e. a pumping mechanism, that allows controlled, variable flow rate.
- a pumping mechanism that allows controlled, variable flow rate.
- the flow control unit cooperates with the control unit, which provides the latter with control signals for maintaining or adjusting the flow rate.
- the pumping mechanism can comprise a pump of any kind available in the market, such as a peristaltic pump, piston pumps etc.
- the pump can be adapted to deliver the infusion fluid continuously and/or intermittently and/or sequentially, the latter preferably on the basis of pulses and intermediate pauses with volumes during the pulses of between 1ml to 50ml.
- the device can, in some embodiments, accommodate more than one type of infusion fluid, such as typically by comprising or connecting to more than one infusion fluid container. Such embodiments allow different type of infusion fluid to be available and administered alternatively or in parallel.
- the control unit receives signals and determines based thereon that a change of infusion fluid is desirable, such as for altering the electrolyte content of the infusion fluid being administered, it can send a signal to the flow control unit to halt flow of infusion fluid A and initiate flow of infusion fluid B.
- infusion fluid 'A' and ⁇ ' refer herein to any type of infusion fluid as further described herein, where A and B represent different infusion fluids.
- the unit can deliver simultaneously more than one type of infusion fluid, providing a desired mixture of fluids to the patient.
- the control unit can provide a signal to reduce flow of fluid A by 50% and at the same time turn on flow of fluid B.
- the control unit generally comprises a processor and a memory for receiving and storing signal data, and for storing and executing programs for processing the received signals and controlling the flow control unit, and providing any suitable output signals and/or information as may be desired to implement.
- the control unit provides output signals that indicate at least recommendations for the therapy, most preferably recommendations as to type of infusion fluid to be used with respect to electrolytic content, and/or the output signals control the flow control unit, to increase or decrease (including halting) flow of an infusion fluid, as further described herein.
- control unit is configured to receive input signals from at least one external computer system. This is particularly useful when used in hospitals using electronic patient journal systems that store and make available patient data such as biosignals (blood pressure, pulse, hemoglobin values, etc.), data from analysed patient samples, and data concerning administered therapy, including, but not limited to medicaments and fluids that have been or are being administered.
- patient data such as biosignals (blood pressure, pulse, hemoglobin values, etc.), data from analysed patient samples, and data concerning administered therapy, including, but not limited to medicaments and fluids that have been or are being administered.
- the control unit is in some embodiments able to receive directly input from such at least one external computer system, with a suitable program interface to query the external system for the desired data.
- the control unit prompts a user to feed the unit with desired data from such external computer system, manually, or by entering data files in suitable format (such as, but not limited to csv format or any other suitable format).
- control unit is configured to receive input signals from at least one sensor that determines concentration of at least one electrolyte and provides a signal indicating said concentration.
- sensor can be arranged to determine the concentration of an electrolyte in an infusion fluid connected to the device, such as by arranging a special sampling duct delivering a quantity of fluid to the sensor, which can be but is not limited to at least one ion specific electrode, such as a sodium selective electrode, potassium selective electrode or chloride selective electrode.
- the sampling duct can be arranged in parallel with a delivery duct, such that fluid entering the sampling duct is consumed and discarded, or in-line with the delivery duct, analysing the fluid before it is delivered. Care must be taken to ensure that fluid administered to the patient remains sterile.
- a sensor as described above and sampling duct can also be arranged on the patient, for sampling and analysing an electrolyte in the blood of the patient.
- delivery duct refers to any conventional and useful delivery duct for an infusion fluid, such as a conventional infusion line and needle, well known to the skilled person.
- control unit is configured to receive input signals that are entered by a user, who is typically a doctor or other caretaker.
- the device comprises a user interface with a user information output such as a screen, for prompting the user for input signals to be entered, suitably via a touchpad screen or keyboard.
- a user information output such as a screen
- the user is prompted at least whenever a fresh infusion bag is to be connected to the device and/or on regular time intervals.
- the input signals that are to be entered can, for example, be data defining which type of infusion fluid is connected, most suitably by choosing from a list stored in the memory of the device of typical conventional infusion fluids. Some common infusion fluids are defined below in a non-limiting list. Table 1
- the device prompts the user for input such as every time an emptied or partially emptied bag is disconnected and every time a new bag is connected.
- control unit is configured to receive input signals directly (without user input) from sensors, such as, but not limited to sensors for sensing vital signals or other patient signals (e.g. heart rate, blood pressure, EKG, EEG, temperature, breathing rhythm).
- sensors such as, but not limited to sensors for sensing vital signals or other patient signals (e.g. heart rate, blood pressure, EKG, EEG, temperature, breathing rhythm).
- the control unit is able to receive a combination of input signals, both manually entered and received from sensors and/or external computers, systems, etc.
- signals can be used by the control unit for determining suitable infusion fluid.
- sensors may detect an adverse event, such as heart rate irregularities, which may indicate lack of potassium, then the control unit can respond by giving an output signal with instructions to change the infusion fluid to a fluid with higher potassium content.
- Input signals that can be received from a sensor or system and/or entered in the device and which the device may prompt the user for may be selected from but are not limited to one or more of the following : signal indicating concentration of at least one electrolyte, signal indicating additional infusion fluid that the patient is being or is to be administered, signal indicating medication that the patient is being administered or has received, signal indicating medical condition of patient, signal indicating desired therapeutic body temperature of patient, and signal indicating blood status of patient.
- Blood status in this context may refer to any of various parameters describing status of blood, such as hemoglobin value, platelet count, etc.
- Medical condition in the context herein may refer to any vital signal such as but not limited to pulse, blood pressure, body temperature, or other relevant input parameter defining medical condition.
- the device is connected to one or more temperature sensors that provide the control unit with values indicating the body temperature of the patient.
- the device may further comprise a unit to cool an infusion bag and/or keep it at desired temperature, and/or a sensor sensing the temperature of the infusion fluid in the infusion bag.
- cooled infusion fluid can be administered with this invention and the device described herein.
- the cooled infusion fluid preferably is delivered with a minimum temperature of 3.5°C, preferably 3.6°C, more preferably 3.7°C, more preferably 3.8°C, more preferably 3.9°C and most preferably 4°C and/or cooled infusion fluid is provided at a maximum temperature of 6°C, preferably 5.5°C, more preferably 5.0°C, more preferably 4.5°C, more preferably 4.25°C and most preferably 4.0°C.
- the adjustment device in one embodiment further comprises a fluid temperature unit for measuring and/or controlling the temperature of the medical fluid, and to deliver a respective temperature signal to the control unit.
- the device of the present invention may suitably be arranged also with means to monitor and/or adjust volume being administered by controlling flow rate of IV fluid and monitoring fluid loss from the patient by suitable sensors, or prompting for relevant data to be entered representing fluid loss.
- the device is configured to adjust the volume of one or more medical infusion fluids, the device comprising a.
- the device be configured to minimize shivering of the patient. Shivering is a normal reflex reaction of the body to feeling cold, triggered to maintain homeostasis. Skeletal muscles begin to shake in small movements, creating warmth by expending energy.
- the control unit of the device is configured to receive input signals indicating levels of shivering and to provide output signals indicating one or more recommendation for therapy based on said received input signals, to counteract the shivering.
- the control unit may react by forwarding an output signal to the flow control unit, signaling that the flow rate is to be altered (reduced), and/or the control unit may signal that the temperature of the infusion fluid is to be raised.
- control unit provides an output signal indicating a recommendation, or a signal to a drug delivery device, that the patient be administered an anti-shivering medication, such as but not limited to a medication selected from opiates, tramadol, magnesium sulfate, a2- agonists, physostigmine, doxapram, methylphenidate, and/or 5-HT3 antagonists.
- output signal indicates a recommendation that surface temperature of the patient be affected, such as through the use of blankets, heating pads, or the like.
- Intracranial pressure is the pressure inside the skull and thus in the brain tissue and cerebrospinal fluid (CSF). Increased intracranial pressure (ICP) is one of the major causes of secondary brain ischemia that accompanies a variety of pathological conditions, most notably, traumatic brain injury (TBI), stroke, and intracranial hemorrhages.
- the control unit of the device is further configured to receive input signals indicating intracranial pressure (ICP) and optionally blood pressure of a patient and to provide output signals indicating one or more recommendations for therapy based on said received input signals.
- the device can, in such embodiments, aid in the treatment of patients with elevated ICP.
- the input signals may be provided by a user, from an external computer system, or internally from a component of the device.
- the control unit may be configured to receive input signals indicating the level of intracranial pressure.
- ICP can be measured with invasive or noninvasive methods. Invasive methods normally require an insertion of an ICP sensor into the brain ventricle or parenchymal tissue. ICP can also be measured non-invasively. Several methods for noninvasive measuring of elevated ICP have been proposed : radiologic methods including computed tomography and magnetic resonance imaging, transcranial Doppler, electroencephalography power spectrum analysis, and the audiological and ophthalmological techniques.
- the recommendation provided by the control unit comprises an instruction to administer ICP- reducing medication.
- ICP-reducing medication is intended to mean any biologically active agent or drug or combination of agents or drugs that is administered to a patient for the purpose of reducing ICP.
- Any ICP-reducing agents can be used, such as agents commonly used in hyperosmolar therapy such as mannitol.
- the control unit is configured to provide output signals to a drug delivery device adapted to administer said ICP-reducing medication, where the delivery device is not part of the overall device.
- a drug delivery device includes any means for containing and releasing a drug, wherein the drug is released to a subject.
- drug delivery device refers to any means for containing and releasing a drug, wherein the drug is released into a subject.
- the means for containing is not limited to containment in a walled vessel, but may be any type of containment device, including non-injectable devices (pumps etc.) and injectable devices, including a gel, a viscous or semi-solid material or even a liquid.
- Drug delivery devices may be inhaled, oral, transdermal, parenteral and suppository. Inhaled devices include gaseous, misting, emulsifying and nebulizing bronchial (including nasal) inhalers; oral includes mostly pills; whereas transdermal includes mostly patches. Parenteral includes injectable and non-injectable devices.
- Non-injectable devices may be "implants” or “non- injectable implants” and include e.g., pumps and solid biodegradable polymers. Injectable devices are split into bolus injections that are injected and dissipate, releasing a drug all at once, and depots, that remain discrete at the site of injection, releasing drug over time. Depots include e.g., oils, gels, liquid polymers and non-polymers, and microspheres. Many drug delivery devices are described in Encyclopedia of Controlled Drug Delivery (1999), Edith Mathiowitz (Ed.), John Wiley & Sons, Inc. The term "drug” as used herein, refers to any substance meant to alter animal physiology.
- drug formulation refers to a drug plus a drug delivery device.
- formulation means any drug together with a pharmaceutically acceptable excipient or carrier such as a solvent such as water, phosphate buffered saline or other acceptable substance.
- a formulation may contain a drug and other active agents. It may also contain an excipient, solvent or buffer or stabilizing agent.
- the control unit is configured to provide output signals to a drug delivery device which is part of the overall device.
- the device according to present invention comprises a drug delivery device and wherein the control unit is configured to provide output signals to said drug delivery device.
- Such device may be semi-automated or automated, such that when the ICP is above a certain given value, the control unit automatically provides an output signal to the drug delivery device adapted to deliver ICP-reducing medication to the patient without or with only minimal intervention of medical personnel.
- the device comprises means to detect automatically information on an infusion fluid bag, such as a barcode scanner or the like optical scanner, that reads information provided on suitable infusion bag, such as a barcode strip or other digitally readable label.
- the device Based on the input information received, the device provides to the user recommendations to a user that includes information as to what type of infusion fluid is optimal. As is understood from herein, the recommendations are determined by the control unit so as to maintain a desired and suitable electrolytic balance in the blood stream of the patient. For example, in a patient that is being cooled down by infusion to reduce negative effect on the brain after oxygen deprivation, but that has not lost any significant blood, may receive as initial IV fluid 0,9% NaCI solution, which is generally the most economical IV fluid to use for temperature therapy via IV infusion, and therefore recommended when other more elaborate multi-component fluids are not warranted. When the device has received information that the patient has received a certain number of IV bags, such as e.g.
- a total infusion volume of more than 2,5 L or more than 3 or 3.5 L it may recommend to the user that another fluid be used, that includes further electrolytic components (e.g. Ringer's solution), to maintain an acceptable electrolytic balance in the blood stream.
- another fluid that includes further electrolytic components (e.g. Ringer's solution), to maintain an acceptable electrolytic balance in the blood stream.
- the device may recommend as IV fluid a fluid comprising said electrolyte.
- Examples of such boundaries can be for example, if the patient is determined to have sodium blood levels of less than about 135 mmol/L, potassium levels of less than about 3,5 mmol/L, calcium blood concentration of less than about 1,15 mmol/L, and magnesium concentration of less than about 0,7 mmol/L.
- Other input parameters may as well determine recommended concentration electrolyte content of IV fluid, such as medical precondition of patient, duration of IV treatment, information on drugs administered to the patent, etc.
- the device of the invention can advantageously be configured, so as to fit in a conventional hospital rack system, i.e. a bedside rack for containing one or more modular devices for patient care and/or monitoring.
- the device is configured and designed as a modular unit to fit in such rack.
- the device can, in certain such embodiments, comprise more than a modular unit, for example when it is desired to actively cool the infusion fluid by keeping it in a cooled storage compartment while the fluid is administered.
- Such cooling compartment can be an add-on module.
- Fig. 1 illustrates a principal configuration of the device of the invention.
- the device 1 as shown in Fig. 1 comprises a control unit 20, a flow control unit 40 and an input/output screen 21.
- a typical infusion fluid bag 10 is shown hung on a conventional supporting device. From the bag, a duct 11 provides infusion fluid through the flow control unit 40, which passes the infusion fluid onwards to a patient (not shown) through duct 14.
- An optional input line 61 from an external computer 60 is shown.
- Adjacent to the bag 10 is a barcode scanner/sensor SI for detecting and registering the type of IV fluid bag, providing a signal to the control unit 20.
- input data concerning the type of IV fluid bag is input via the input screen 21.
- Optional sensors S2, S3 are shown which can be connected to a patient, for feeding back signals to the control unit 20 with data indicating electrolyte blood concentration of the patient.
- Bed 30 is shown.
- Bed 30 can comprise a patient and symbolically refer to it.
- the device further suitably will maintain a desired temperature of the IV fluid being administered (such as by containing the bag in a specialized compartment and/or by thermally insulating it), and preferably monitors the temperature of outgoing fluid and/or the IV bag being administered, and the body temperature of the patient. Such values, when monitored and registered by the device, are used to calculate and set a suitable flow rate.
- the device comprises a temperature control unit that controls the temperature of IV fluid flowing from the device.
- Another or a plurality of reservoir(s) 10 can also be provided to provide either different infusion fluids as described above and/or the same infusion fluids for different purposes and/or with different temperatures.
- a plurality of reservoir ducts 11 are provided (not shown).
- a patient in need of therapeutic hypothermia treatment is treated with the use of a device of the present invention.
- the device prompts the user to input measured values of electrolytes that include the sodium concentration in the patient's blood, and further prompts for input of a value corresponding to the body weight of the patient.
- the user inputs the value 110 mmol/L, which is the measured sodium blood concentration value for the particular patient, and 60 kg as patient body weight.
- the device in this embodiment considers a sodium value less than 135 mmol/L as a deficient value.
- the device further prompts the user to input the measured potassium concentration in the blood; if a value less than 3,5 mmol/L is added, the device recommends as IV solution Ringer's solution, containing 4,0 mmol/L potassium, and calculates the total volume which is suitable to overcome the potassium deficiency.
- the present invention also covers the exact terms, features, values and ranges etc. in case these terms, features, values and ranges etc. are used in conjunction with terms such as about, around, generally, substantially, essentially, at least etc. (i.e., "about 3” shall also cover exactly 3 or “substantially constant” shall also cover exactly constant).
- the term “at least one” should be understood as meaning “one or more”, and therefore includes both embodiments that include one or multiple components.
- dependent claims that refer to independent claims that describe features with “at least one” have the same meaning, both when the feature is referred to as "the” and “the at least one”. It will be appreciated that variations to the foregoing embodiments of the invention can be made while still falling within the scope of the invention.
- Alternative features serving the same, equivalent or similar purpose can replace features disclosed in the specification, unless stated otherwise.
- each feature disclosed represents one example of a generic series of equivalent or similar features.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2015187792 | 2015-09-30 | ||
PCT/EP2016/073245 WO2017055441A1 (en) | 2015-09-30 | 2016-09-29 | Electrolyte adjustment infusion system and method |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3355971A1 true EP3355971A1 (en) | 2018-08-08 |
Family
ID=62748561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16788434.5A Withdrawn EP3355971A1 (en) | 2015-09-30 | 2016-09-29 | Electrolyte adjustment infusion system and method |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP3355971A1 (en) |
-
2016
- 2016-09-29 EP EP16788434.5A patent/EP3355971A1/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220386951A1 (en) | Autonomous drug delivery system | |
Lichtenberger | Shock and cardiopulmonary-cerebral resuscitation in small mammals and birds | |
US11707571B2 (en) | Hierarchical adaptive closed-loop fluid resuscitation and cardiovascular drug administration system | |
US20180280620A1 (en) | Shivering adjustment infusion system and method | |
CN110730989B (en) | Personalized renal failure chronic care system and method | |
WO2017055450A1 (en) | Intracranial pressure adjustment infusion system and method | |
US20180289890A1 (en) | Volume adjustment infusion system and method | |
US20180280615A1 (en) | Electrolyte adjustment infusion system and method | |
EP3355971A1 (en) | Electrolyte adjustment infusion system and method | |
Bader et al. | Brain tissue oxygen monitoring in severe brain injury, II: Implications for critical care teams and case study | |
Abeles et al. | The use of conscious sedation for outpatient dermatologic surgical procedures | |
US20180289535A1 (en) | Temperature adjustment infusion system and method | |
EP3355776A1 (en) | Intracranial pressure adjustment infusion system and method | |
Donohoe | Fluid therapy for veterinary technicians and nurses | |
Kerr et al. | Cardiopulmonary effects and recovery characteristics associated with 2 sedative protocols for assisted ventilation in healthy neonatal foals | |
WO2019169026A1 (en) | Autonomous drug delivery system | |
Kumuthapriya et al. | Internet of Things Based Revolutionizing Healthcare Industry with Anesthesia Machine Control: The Future of Medical Technology | |
SOLONIN et al. | INFUSION THERAPY IN THE PERIOPERATIVE PERIOD IN DOGS AND CATS. | |
JPWO2020188333A5 (en) | ||
Reed | Total Intravenous Anesthesia | |
Farkas-Hirsch et al. | Implementation of continuous subcutaneous insulin infusion therapy: An overview | |
Beseda et al. | Therapeutic Hypothermia After Cardiac Arrest and Return of Spontaneous Circulation: It’s Complicated | |
Platt | Traumatic head injuries in cats | |
Brearley | Perioperative fluid therapy | |
Gunkel | Critical foal anesthesia. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20180427 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ROTH, MATTHIAS Inventor name: REICHTHALHAMMER, THOMAS |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200603 |